Most searched codes in this drug class
Monthly US Google searches for the bare code (Google Ads, October 2026) show which entries coders and billers look up most; demand is one input to the index decision for each page and to which pages the hubs link first.
| Code | Description | Payment limit | Searches / month |
|---|---|---|---|
| Q5136 | Inj. denosumab-bbdz, 1 mg | $26.991 | 880 |
| Q5103 | Injection, inflectra | $28.456 | 720 |
| Q5111 | Injection, udenyca 0.5 mg | $128.967 | 720 |
| Q5115 | Inj truxima 10 mg | $35.988 | 720 |
| Q5106 | Inj retacrit non-esrd use | $8.171 | 590 |
| Q5108 | Injection, fulphila | $55.964 | 590 |
| Q5107 | Inj mvasi 10 mg | $28.294 | 480 |
| Q5147 | Inj, aflibercept-ayyh, 1 mg | $763.376 | 480 |
| Q5101 | Injection, zarxio | $0.338 | 390 |
| Q5119 | Inj ruxience, 10 mg | $5.792 | 590 |
Codes in this drug class
52 of the 55 codes carry a published October 2026 ASP payment limit, 3 show their OPPS rate instead; the remaining codes are priced by contractors or carry a limit of zero in the file. The table lists the 52 codes whose reference pages are indexed; the other 3 follow as a list.
| Code | Descriptor | Unit | Limit | MUE | Col-2 pairs | Articles |
|---|---|---|---|---|---|---|
| Q5098 | Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg | 1 MG | $9.27 | 520 | — | — |
| Q5099 | Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg | 1 MG | $2.89 | 520 | — | — |
| Q5100 | Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg | 1 MG | $3.08 | 520 | — | — |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 1 MCG | $0.338 | 1500 | — | yes |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 10 MG | $28.456 | 150 | — | yes |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | 100 UNITS | $0.817 | 100 | — | yes |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 1000 UNITS | $8.171 | 60 | — | yes |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 10 MG | $28.294 | 230 | — | yes |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 0.5 MG | $55.964 | 12 | — | yes |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 1 MCG | $0.329 | 1500 | — | yes |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 0.5 MG | $128.967 | 12 | — | yes |
| Q5112 | Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | 10 MG | $32.791 | 120 | — | — |
| Q5113 | Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg | 10 MG | $55.295 | 120 | — | — |
| Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | 10 MG | $29.507 | 120 | — | — |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 10 MG | $35.988 | 150 | — | yes |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | 10 MG | $11.271 | 120 | — | — |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 10 MG | $63.871 | 120 | — | — |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 10 MG | $25.939 | 230 | — | yes |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | 0.5 MG | $302.247 | 12 | — | yes |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 10 MG | $34.686 | 150 | — | yes |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 0.5 MG | $141.289 | 12 | — | yes |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 10 MG | $21.083 | 150 | — | yes |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 0.1 MG | $249.493 | 10 | — | yes |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | 1 MCG | $0.308 | 1800 | — | yes |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | 10 MG | $79.982 | 230 | — | yes |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | 0.5 MG | $163.948 | 12 | — | yes |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 0.1 MG | $81.13 | 10 | — | yes |
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | 10 MG | $21.139 | 230 | — | yes |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg | 0.5 MG | $94.292 | 12 | — | yes |
| Q5133 | Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg | 1 MG | $4.706 | 1200 | — | — |
| Q5134 | Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg | 1 MG | $24.397 | 300 | — | — |
| Q5135 | Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg | 1 MG | $4.37 | 1200 | — | — |
| Q5136 | Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg | 1 MG | $26.991 | 120 | — | yes |
| Q5138 | Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg | 1 MG | $2.273 | 520 | — | — |
| Q5146 | Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg | 10 MG | $30.255 | 120 | — | — |
| Q5147 | Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg | 1 MG | $763.376 | 4 | — | yes |
| Q5148 | Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram | 1 MCG | $1.026 | 1500 | — | yes |
| Q5151 | Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg | 2 MG | $31.547 | 600 | — | yes |
| Q5152 | Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg | 2 MG | $40.412 | 600 | — | yes |
| Q5154 | Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg | 5 mg | $46.61 OPPS | — | — | yes |
| Q5156 | Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg | 1 MG | $3.098 | — | — | — |
| Q5157 | Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg | 1 MG | $24.002 | — | — | yes |
| Q5158 | Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg | 1 MG | $28.702 | — | — | yes |
| Q5160 | Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg | 10 MG | $82.139 | 230 | — | yes |
| Q5161 | Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg | 1 MG | $27.509 | — | — | — |
| Q5162 | Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg | 1 MG | $15.336 | — | — | yes |
| Q5166 | Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg | 1 mg | $29.72 OPPS | — | — | yes |
| Q5167 | Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg | 1 MG | $7.681 | — | — | yes |
| Q5168 | Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg | 0.1 MG | $26.384 | — | — | yes |
| Q5169 | Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg | 0.5 MG | $519.481 | — | — | yes |
| Q9998 | Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg | 1 MG | $10.48 | 520 | — | — |
| Q9999 | Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg | 1 MG | $13.246 | 520 | — | — |
Show the other 3 codes (pages not yet in search results)
- Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg · limit $25.649
- Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg · limit $5.792
- Q5172 Injection, filgrastim-laha (filkri), biosimilar, 1 microgram · OPPS $0.74
How to read this table
The limit is the Medicare Part B payment allowance per billing unit for the quarter shown, not per dose: multiply it by the units that the administered quantity divided by the descriptor unit produces. Codes marked OPPS have no ASP limit and show the hospital outpatient rate per unit instead. The MUE column is the practitioner-setting Medically Unlikely Edit, the maximum units CMS expects on one date of service; facility and DME limits can differ and appear on each code page. Column-2 pairs counts the active NCCI procedure-to-procedure edits in which the code is the bundled component, and Articles marks codes that at least one Medicare Administrative Contractor lists in a current Billing and Coding Article with covered diagnosis codes. Codes without a published limit are contractor-priced or carry a zero limit in the CMS file.
In QuickIntell research
- October 2026 ASP movers report: The 75 drug codes whose payment limit moved 20% or more since July 2026, and the 37 priced for the first time.
- October 2026 HCPCS update report: The codes CMS added and discontinued in the latest quarterly release, with replacements; the 2026 roll-up covers every quarter.
- 2026 Q4 most-bundled codes report: The codes NCCI bundles most often as column 2, and the 12 Part B drug codes it bundles at all.
- J codes by drug name: Find the J code, or every code, for a drug by generic or brand name.
Where QuickIntell fits in drug billing
QuickCode supports qualified coder review of the units, NDC and edit questions these tables answer before the claim leaves, and QuickRCM carries the claim-readiness and denial work for drug lines with human review.
Frequently asked questions
How many codes are in biosimilar drug codes?
55 Part B drug codes in this drug class: 52 carry an ASP payment limit in the October 2026 file and 3 are paid separately under OPPS without an ASP limit; 52 have enough joined CMS data (MUE, NCCI, OPPS, ASC or coverage) to be published as full reference pages.
Which payers use these payment limits?
Medicare Part B contractors apply the ASP limits directly. Medicaid programs and commercial payers publish their own fee schedules, which often reference ASP but at different percentages.
Why do some codes show no MUE?
CMS withholds some MUE values as confidential and applies them without publication; others have no unit limit. A code with no published MUE can still deny for units when the quantity is implausible for the dose.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-10. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
Disclaimer
Operational reference compiled from CMS publications. Payment limits are Medicare national amounts; other payers differ. CPT codes appear as numbers only. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.